Eleven postmenopausal women with Parkinson disease and levodopa-induced peak-dose dyskinesias underwent a double-blind, placebo-controlled, crossover study. The active treatment consisted of estrogen replacement therapy for 12 weeks, followed by medroxyprogesterone acetate for 2 weeks. Estrogen replacement therapy-medroxyprogesterone acetate administration significantly improved peak dose dyskinesia without worsening motor disability, thus suggesting a possible benefit on dyskinesias in postmenopausal Women with Parkinson disease.
Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: A crossover trial
Arabia G;
2007-01-01
Abstract
Eleven postmenopausal women with Parkinson disease and levodopa-induced peak-dose dyskinesias underwent a double-blind, placebo-controlled, crossover study. The active treatment consisted of estrogen replacement therapy for 12 weeks, followed by medroxyprogesterone acetate for 2 weeks. Estrogen replacement therapy-medroxyprogesterone acetate administration significantly improved peak dose dyskinesia without worsening motor disability, thus suggesting a possible benefit on dyskinesias in postmenopausal Women with Parkinson disease.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
